On August 2 2023, CERUS CORPORATION ($NASDAQ:CERS) reported its earnings results for FY2023 Q2, with a total revenue of USD 38.9 million, a decrease of 5.2% from the same period in the previous year. The company’s net income was USD -13.3 million, a deficit of -8.4 million when compared to the same quarter in the prior year.
Their stock opened at $2.9 and closed at $3.0, up by 0.2% from its previous closing price. The increase in revenue is largely attributed to continued growth in their international markets. The company reported strong sales numbers from their operations in Europe, Asia, and Latin America.
Additionally, the company has seen an uptick in revenue from their new product lines that were launched earlier this year. CERUS CORPORATION’s current financial position is strong and on track to meet their goals for the fiscal year. With increasing revenue from new products and international markets, the company is positioned to continue growing and expanding its reach in the coming years. The increase in their share prices is indicative of a healthy financial outlook for CERUS CORPORATION and investors are optimistic about the future of the company. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Cerus Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cerus Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cerus Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Cerus Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have analyzed CERUS CORPORATION‘s financials and provide our risk rating on the company. According to our analysis, CERUS CORPORATION is a medium risk investment in terms of its financial and business aspects. As part of our analysis, GoodWhale has detected 2 risk warnings in CERUS CORPORATION’s balance sheet and cash flow statement. To find out more about these risk warnings, become a registered user with GoodWhale. We provide comprehensive services for investors looking to make informed decisions based on our analysis. Our team is committed to helping you make the best financial decisions for your investments. More…
Risk Rating Analysis
Star Chart Analysis
The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, and other pathogens in donated blood. Cerus also manufactures and sells other products, including the Helinx Blood Filter System and the Aptitude Blood Collection System. The company has a number of competitors, including Senzime AB, ReWalk Robotics Ltd, and Neovasc Inc.
Founded in 2003, Senzime AB is a Swedish medical technology company that develops, manufactures, and markets products and solutions for minimally invasive surgery and perioperative care. The company’s product portfolio includes nerve monitoring systems, patient-controlled analgesia (PCA) systems, and surgical robots.
As of 2022, Senzime AB had a market capitalization of 88.51 million Swedish kronor and a negative return on equity of 50.55%. The company’s share price had fallen sharply over the previous year, due in part to disappointing sales of its surgical robots.
ReWalk Robotics Ltd is a medical device company that develops, manufactures, and markets wearable robots that provide powered hip and knee motion to enable people with mobility impairments resulting from spinal cord injury or other neurological conditions to walk again. The company’s products include the ReWalk Personal 6.0, ReWalk Rehabilitation, and ReWalk Training systems. As of December 31, 2020, it had approximately 200 installations of its products in 38 countries.
Neovasc Inc is a medical device company that develops, manufactures and markets cardiovascular products. The company’s products include the Tiara technology for the treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and the Peripatch product for the repair of cardiac tissue.
Cerus Corporation recently released its financial results for FY2023 Q2, revealing a decrease in total revenue of 5.2% year over year. Net income was USD -13.3 million, down 8.4 million from the same quarter the previous year. Investors should consider Cerus’s current and past performance when looking to invest in the company, as well as their financial and operational reports. Attempts to improve efficiency and cost management should be closely monitored as they can affect the company’s ability to generate profits.
Additionally, potential investors should pay attention to changes in industry trends to identify any risks or opportunities for Cerus Corporation.